<DOC>
	<DOCNO>NCT02074241</DOCNO>
	<brief_summary>The purpose study try figure bio-markers chemosensitivity adjuvant chemotherapy bladder cancer .</brief_summary>
	<brief_title>Molecular Markers Chemosensitivity Bladder Cancer</brief_title>
	<detailed_description>Figure bio-markers chemosensitivity adjuvant chemotherapy bladder cancer .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>1 . Male female , 18 year age old , estimate life expectancy ≥ 6 month . 2 . .Gone standardize radical cystectomy pelvic lymphadenectomy inoperable . 3 . Transitional cell carcinoma bladder , stage pT3N0M0 , T2N1M0T34N12M1.Transitional cell carcinoma may without squamous cell carcinoma and/or adenocarcinoma component . 4 . Electrocorticography ( ECOG ) performance status 02 . 5 . Blood routine : Absolute neutrophil count ( ANC ) ≥ 1500/μL , White blood cell count ≥ 3000/μLPlatelets ≥ 100,000/μL , Hemoglobin ≥ 10.0 g/dL , 6 . Total serum bilirubin≤ 1.5 x upper limit normal ( ULN ) .Serum aspartate transaminase ( AST ; serum glutamic oxaloacetic transaminase ( SGOT ) ) serum alanine transaminase ( ALT ; serum glutamic pyruvic transaminase ( SGPT ) ) ≤ 2.5 x upper limit normal ( ULN ) . 7 . Creatinine clearance rate , Ccr ≥ 60 % 8 . ECG：no arrhythmia , myocardial infarction . Signed date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrollment . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . 1 . Past history systemic chemotherapy 2 . Serious heart lung dysfunction . 3 . Associated central peripheral neuropathy great 2 grade .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>